Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocatinlimab PK study in healthy Chinese subjects
NCT06214481Phase 1Completed
- Sponsor
- Amgen
- Start
- Jan 2024
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rocatinlimab in atopic dermatitis (AD), sponsored by Amgen. Primary endpoints: Maximum Observed Plasma Concentration at 126 days, Area Under the Serum Concentration Time Curve from Time Zero to the Time of the Last Measurable Concentration at 126 days and 1 more. Started Jan 2024; status: completed.
02
Drugs
rocatinlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06214481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06214481.